MedTrace Logo

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

NCT01245530 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2011-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.

Conditions

  • Alzheimer Type Dementia

Interventions

DRUG

Aricept

Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks

DRUG

INM-176

INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks

Sponsors & Collaborators

  • Whanin Pharmaceutical Company

    lead INDUSTRY

Principal Investigators

  • SangYoon Kim, MD · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-02-28
Completion
2011-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245530 on ClinicalTrials.gov